Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody

Summary Primary cutaneous B cell lymphomas have a high recurrence rate after treatment with surgery and/or local radiation therapy. Two men are described in whom radiotherapy‐relapsing cutaneous B‐cell lymphomas were successfully treated with the monoclonal anti‐CD20 antibody rituximab. Both patients had a complete response with no recurrence at follow‐up at 17 and 24 months for the large B‐cell lymphoma of the leg and the follicle centre cell lymphoma, respectively. These are two of the few cases in the literature showing that rituximab is an effective and well‐tolerated treatment for radiotherapy‐relapsing primary cutaneous B cell lymphoma.